Article Text

Download PDFPDF
MUC5B: a good target for future therapy in pulmonary fibrosis?
  1. Rahul Mahida,
  2. Alice M Turner
  1. Centre for Translational Inflammation Research, University of Birmingham, QEHB, Birmingham, UK
  1. Correspondence to Alice M Turner, Centre for Translational Inflammation Research, University of Birmingham, QEHB, Mindelsohn Way, Birmingham B15 2WB, UK; a.m.wood{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Idiopathic pulmonary fibrosis (IPF), sarcoidosis and systemic sclerosis can each cause diffuse parenchymal lung disease involving alveolar epithelial abnormalities, and manifest as interstitial lung fibrosis. Systemic sclerosis is an autoimmune connective tissue disease and sarcoidosis is a multisystem granulomatous disease; the development of lung fibrosis in both conditions generally indicates a poor prognosis. IPF is a progressive disease which is thought to occur after recurrent injury to the alveolar epithelium followed by dysregulation of cellular homoeostasis, abnormal repair and excessive deposition of extracellular matrix, ultimately leading to loss of lung function.1 Mortality 3–5 years after diagnosis of IPF is 50%, and treatment options are currently limited.

Seibold et al2 have previously shown that a variant single-nucleotide polymorphism (SNP) in the promoter region of an airway mucin gene (MUC5B) is associated with greatly increased production of MUC5B, and with pulmonary fibrosis. This suggested that dysregulated MUC5B expression in the lung may be key to the pathogenesis of pulmonary fibrosis. One hypothesis is that an excess of MUC5B causes bronchiolar plugging and impairs mucosal host defence, reducing clearance …

View Full Text


  • Contributors RM and AMT drafted the manuscript; AMT acts as guarantor.

  • Funding AMT has current funding from the Wellcome Trust, NIHR HTA (grant number 11/27/01), Alpha 1 Foundation, UHB charities and Linde REALfund; none of her funders had any input to this manuscript.

  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.

Linked Articles

  • Airwaves
    Andrew Bush Ian Pavord